Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation

od Bone, H. G., Walter, M. A., Hurley, M. E., Epstein, S.
izdano v Osteoporos Int (2017)

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

od Barrett-Connor, E., Swern, A. S., Hustad, C. M., Bone, H. G., Liberman, U. A., Papapoulos, S., Wang, H., de Papp, A., Santora, A. C.
Izdano 2011

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

od Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J-Y., Muñoz Torres, M., Wang, A., Bone, H. G.
izdano v Osteoporos Int (2018)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

od Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.
izdano v Osteoporos Int (2019)

Improved adherence with PTH(1–84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis

od Black, D. M., Bilezikian, J. P., Greenspan, S. L., Wüster, C., Muñoz-Torres, M., Bone, H. G., Rosen, C. J., Andersen, H. S., Hanley, D. A.
izdano v Osteoporos Int (2012)

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

od Bone, H. G., Dempster, D. W., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., Verbruggen, N., Leung, A. T., Lombardi, A.
izdano v Osteoporos Int (2014)

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture T...

od Bone, H. G., Dempster, D. W., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., Verbruggen, N., Leung, A. T., Lombardi, A.
izdano v Osteoporos Int (2015)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

od Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, C., Wagman, R. B., Cummings, S. R.
izdano v J Clin Endocrinol Metab (2016)

Epidemiology of severe sepsis and septic shock in Germany: results from the German 'Prevalence' study

od Brunkhorst, FM, Engel, C, Reinhart, K, Bone, H-G, Brunkhorst, R, Burchardi, H, Eckhardt, K-U, Forst, H, Gerlach, H, Grond, S, Gründling, M, Huhle, G, Oppert, M, Olthoff, D, Quintel, M, Ragaller, M, Rossaint, R, Seeger, W, Stüber, F, Weiler, N, Welte, T, Loeffler, M
Izdano 2005

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

od Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.
izdano v Osteoporos Int (2015)

Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German I...

od Reinhart, K., Brunkhorst, F. M., Bone, H.-G., Bardutzky, J., Dempfle, C.-E., Forst, H., Gastmeier, P., Gerlach, H., Gründling, M., John, S., Kern, W., Kreymann, G., Krüger, W., Kujath, P., Marggraf, G., Martin, J., Mayer, K., Meier-Hellmann, A., Oppert, M., Putensen, C., Quintel, M., Ragaller, M., Rossaint, R., Seifert, H., Spies, C., Stüber, F., Weiler, N., Weimann, A., Werdan, K., Welte, T.
Izdano 2010